Green Line Business Group

06/03/2026

Protections must be a priority in Delaware. We applaud U.S. Senator Chris C***s and our Delaware innovation leaders who are working hard to protect innovation in the First State. Read the Delaware Business Times op-ed "Delaware’s innovation legacy depends on strong IP protections" to learn more.

A powerful collaboration of Delaware business and leaders. This viewpoint was co-authored by leaders from the Tech Council of Delaware, Delaware IP Alliance, Delaware State Chamber, Delaware Black Chamber of Commerce, and NCC Chamber of Commerce, bringing together diverse perspectives on the future of innovation and economic growth in our state.

"We are fortunate to have U.S. Senator Chris C***s’s experience and steady leadership anchoring Delaware’s voice on these issues. His ‘A+’ rating on Council for Innovation Promotion’s scorecard did not happen overnight; it reflects years of bipartisan, practical work to ensure that creators and companies can confidently bring new ideas to market. He understands that strong patents and reliable IP protections are what allow businesses to take the risks required to research, develop, and commercialize new technologies.

The need for robust protections spans every corner of Delaware’s economy—from life sciences and advanced manufacturing to technology, agriculture, and the creative industries. Inventors, entrepreneurs, and workers alike depend on a system that rewards originality and guards against misuse or theft."

Read the full article in Delaware Business Times:

https://delawarebusinesstimes.com/news/viewpoint-ip-protections/

04/12/2026

Texas Congressman Nathaniel Moran (TX-01) recently issued a stark warning in a commentary for The Hill titled "America’s medicine cabinet runs through Beijing," highlighting a dangerous shift in the global pharmaceutical landscape.

Moran argues that the United States has reached a perilous turning point regarding its medical supply chain. Currently, the U.S. is deeply beholden to China for essential drug components, even as Beijing aggressively moves to dominate clinical trials and drug production. According to Moran, this lopsided relationship is more than a trade imbalance; it is a direct threat to national security and the well-being of American patients. Any escalation in geopolitical friction could effectively sever the American public's access to vital medications.

While the U.S. has historically been the pioneer of medical breakthroughs, Moran emphasizes that this leadership is under siege. He calls on Congress to implement long-term reforms that incentivize domestic R&D and manufacturing to counter China’s rapid expansion in the sector.

"Congress must continue to focus on policies that spur pharmaceutical innovation at home beyond the immediate future because China has and will continue to outpace the U.S.," Moran writes. He maintains that the next wave of medical miracles must be "discovered, developed, and produced" on American soil to ensure the safety of the free world.

Read the full piece here: https://thehill.com/opinion/healthcare/5817380-us-china-drug-innovation/

The United States is increasingly reliant on China for pharmaceuticals, with the potential for the Chinese Communist Party to gain control of the global supply chain, posing a national security ris…

01/21/2026

U.S. Senator Lisa Blunt Rochester, U.S. Senator Chris C***s and Congresswoman Sarah McBride we thank you for your support! Let's pass the now!